Epinephrine Segment has the Largest Share of Medication Type in the Europe Anaphylaxis Treatment Market during 2021-2028
According to a new market research study on “Europe Anaphylaxis Treatment Market to 2028 - COVID-19 Impact and Regional Analysis and Forecast by Medication Type, Route of Administration, Allergy Type, and Distribution Channel,” is expected to reach US$ 987.2 million by 2028 from US$ 534.0 million in 2021. The market is estimated to grow at a CAGR of 9.2% from 2021 to 2028. The report provides trends prevailing in the Europe anaphylaxis treatment market along with the drivers and restraints pertaining to the market growth. The growth of this market is estimated to grow owing to key driving factors such as the rising incidence of anaphylaxis and recent approvals of epinephrine are the key factors driving the market growth. However, the market is expected experiencing slow growth during the forecast period owing to the poor accessibility to epinephrine auto-injectors in low-income countries.
The rapid growth of COVID-19 cases in Europe has had a major impact on the European economy. Spain, Italy, Germany, France, and the United Kingdom are among the European countries most affected. In collaboration with the European Academy of Allergy and Clinical Immunology (EAACI), it published “Allergy and Its Impact on Asthma (ARIA).” Experts in their respective fields recently published a compendium with answers to 150 commonly asked questions about COVID-19 and allergic diseases. Furthermore, readers can put further questions regarding this “living” compendium electronically to the authors, and their answers will be available through a new category in the journal’s webpage. Besides, EAACI, in collaboration with ARIA, has provided recommendations on operational plans and practical procedures for ensuring optimal standards in the daily clinical care of patients with allergic diseases whilst ensuring the safety of patients and healthcare workers. Therefore, growing awareness of allergy linked to COVID-19 in Europe during is likely to demand for anaphylaxis treatment and supply in COVID Pandemic, hence it can boost the growth of the anaphylaxis treatment market.
The market for anaphylaxis treatment market is segmented into medication type, route of administration, allergy type, and distribution channel. Based on medication type, the anaphylaxis treatment market is segmented epinephrine, antihistamines, steroids, beta-agonist, and others. In 2020, epinephrine segment accounted for the highest share of the market. The growth of the epinephrine is attributed due to easy access to the epinephrine, rising incidences of allergic reactions and growing government policies to access epinephrine to school-going children. Additionally, the rise in the number of a product launch for generic version epinephrine is key factor responsible for the growth of the market. For instance, in July 2019, Sandoz, a Novartis AG division, has launched its generic pre-filled Symjepi epinephrine shots across the country.
Amneal Pharmaceuticals Inc. Mylan N.V. BIOPROJET, Abbott, Pfizer Inc. Glaxosmithkline Plc. Merck and Co. Inc. Teva Pharmaceutical Industries Ltd. and ALK-ABELLó are among the leading companies in the Europe anaphylaxis treatment market. The companies are focused on adopting organic growth strategies such as product launches and expansions to sustain their position in the dynamic market. For instance, in December 2020, GSK Consumer Healthcare launched Otrivin Breathe clean, a saline wash with the moisturizing benefit of natural glycerin. The daily usage of the nasal spray washes out the allergens, pollutants, and debris that are trapped in the nasal passage, helping in the removal of allergy symptoms, and thus maintaining nasal hygiene.
The rapid growth of COVID-19 cases in Europe has had a major impact on the European economy. Spain, Italy, Germany, France, and the United Kingdom are among the European countries most affected. In collaboration with the European Academy of Allergy and Clinical Immunology (EAACI), it published “Allergy and Its Impact on Asthma (ARIA).” Experts in their respective fields recently published a compendium with answers to 150 commonly asked questions about COVID-19 and allergic diseases. Furthermore, readers can put further questions regarding this “living” compendium electronically to the authors, and their answers will be available through a new category in the journal’s webpage. Besides, EAACI, in collaboration with ARIA, has provided recommendations on operational plans and practical procedures for ensuring optimal standards in the daily clinical care of patients with allergic diseases whilst ensuring the safety of patients and healthcare workers. Therefore, growing awareness of allergy linked to COVID-19 in Europe during is likely to demand for anaphylaxis treatment and supply in COVID Pandemic, hence it can boost the growth of the anaphylaxis treatment market.
The market for anaphylaxis treatment market is segmented into medication type, route of administration, allergy type, and distribution channel. Based on medication type, the anaphylaxis treatment market is segmented epinephrine, antihistamines, steroids, beta-agonist, and others. In 2020, epinephrine segment accounted for the highest share of the market. The growth of the epinephrine is attributed due to easy access to the epinephrine, rising incidences of allergic reactions and growing government policies to access epinephrine to school-going children. Additionally, the rise in the number of a product launch for generic version epinephrine is key factor responsible for the growth of the market. For instance, in July 2019, Sandoz, a Novartis AG division, has launched its generic pre-filled Symjepi epinephrine shots across the country.
Amneal Pharmaceuticals Inc. Mylan N.V. BIOPROJET, Abbott, Pfizer Inc. Glaxosmithkline Plc. Merck and Co. Inc. Teva Pharmaceutical Industries Ltd. and ALK-ABELLó are among the leading companies in the Europe anaphylaxis treatment market. The companies are focused on adopting organic growth strategies such as product launches and expansions to sustain their position in the dynamic market. For instance, in December 2020, GSK Consumer Healthcare launched Otrivin Breathe clean, a saline wash with the moisturizing benefit of natural glycerin. The daily usage of the nasal spray washes out the allergens, pollutants, and debris that are trapped in the nasal passage, helping in the removal of allergy symptoms, and thus maintaining nasal hygiene.
The report segments the Europe Anaphylaxis Treatment market as follows:
By Medication Type
- Epinephrine
- Antihistamines
- Steroids
- Beta-Agonist
- Others
By Route of Administration
- Parenteral
- Oral
- Others
By Allergy Type
- Food Allergy
- Medications
- Insect Stings
- Others
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Others
By Country
- Europe
- Germany
- UK
- France
- Spain
- Italy
- Rest of Europe
Reasons to buy:
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the Europe anaphylaxis treatment market
- Highlights key business priorities in order to assist companies to realign their business strategies
- The key findings and recommendations highlight crucial progressive industry trends in the Europe anaphylaxis treatment market, thereby allowing players across the value chain to develop effective long-term strategies
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
- Scrutinize in-depth Europe market trends and outlook coupled with the factors driving the anaphylaxis treatment market, as well as those hindering it
- Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing and distribution
Table of Contents
1. Introduction
3. Research Methodology
4. Europe Anaphylaxis Treatment Market - Market Landscape
5. Europe Anaphylaxis Treatment Market - Key Market Dynamics
6. Anaphylaxis Treatment Market - Europe Analysis
7. Europe Anaphylaxis Treatment Market Analysis and Forecasts To 2028 - By Medication Type
8. Anaphylaxis Treatment Market Analysis - By Route of Administration
9. Europe Anaphylaxis Treatment Market Analysis and Forecasts To 2028 - By Allergy Type
10. Europe Anaphylaxis Treatment Market Analysis and Forecasts to 2028 - By Distribution Channel
11. Anaphylaxis Treatment Market Revenue and Forecasts to 2028 - Geographical Analysis
12. Impact Of COVID-19 Pandemic on Europe Anaphylaxis Treatment Market
13. Industry Landscape
14. COMPANY PROFILES
15. Appendix
List of Tables
List of Figures
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Amneal Pharmaceuticals Inc.
- Mylan N.V.
- Abbott
- Pfizer Inc.
- Glaxosmithkline Plc.,
- Merck And Co., Inc.
- Teva Pharmaceutical Industries Ltd.
- ALK-Abelló
- BIOPROJET
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 156 |
| Published | July 2021 |
| Forecast Period | 2021 - 2028 |
| Estimated Market Value ( USD | $ 534 Million |
| Forecasted Market Value ( USD | $ 987.2 Million |
| Compound Annual Growth Rate | 9.2% |
| Regions Covered | Europe |
